SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 38.12 |
Enterprise Value ($M) | 36.72 |
Book Value ($M) | 1.90 |
Book Value / Share | 0.07 |
Price / Book | 20.08 |
NCAV ($M) | 1.39 |
NCAV / Share | 0.05 |
Price / NCAV | 27.36 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -4.17 |
Return on Assets (ROA) | -0.88 |
Return on Equity (ROE) | -0.95 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.45 |
Current Ratio | 3.45 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 1.96 |
Assets | 2.47 |
Liabilities | 0.57 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -8.31 |
Net Income | -8.20 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -8.09 |
Cash from Investing | 0.00 |
Cash from Financing | -0.06 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
264 | 3,279 | 8.05 | |
2,968 | 13,854 | 21.42 | |
49 | 3,547 | 1.38 | |
1,535 | 1,718 | 89.35 | |
45 | 330 | 13.64 | |
(click for more detail) |
Similar Companies | |
---|---|
ALRN – Aileron Therapeutics, Inc. | ALVR – AlloVir, Inc. |
ALZN – Alzamend Neuro, Inc. | ANIX – Anixa Biosciences, Inc. |
APM – Aptorum Group Limited |
Financial data and stock pages provided by
Fintel.io